Abstract:Dry eye disease (DED) can arise from a variety of factors, including inflammation, meibomian gland dysfunction (MGD), and neurosensory abnormalities. Individuals with DED may exhibit a range of clinical signs, including tear instability, reduced tear production, and epithelial disruption, that are driven by different pathophysiological contributors. Those affected often report a spectrum of pain and visual symptoms that can impact physical and mental aspects of health, placing an overall burden on an individual's well-being. This cumulative impact of DED on an individual's activities and on society underscores the importance of finding diverse and effective management strategies. Such management strategies necessitate an understanding of the underlying pathophysiological mechanisms that contribute to DED in the individual patient. Presently, the majority of approved therapies for DED address T cell-mediated inflammation, with their tolerability and effectiveness varying across different studies. However, there is an emergence of treatments that target additional aspects of the disease, including novel inflammatory pathways, abnormalities of the eyelid margin, and neuronal function. These developments may allow for a more nuanced and precise management strategy for DED. This review highlights the recent pharmacological advancements in DED therapy in the United States. It discusses the mechanisms of action of these new treatments, presents key findings from clinical trials, discusses their current stage of development, and explores their potential applicability to different sub-types of DED. By providing a comprehensive overview of products in development, this review aims to contribute valuable insights to the ongoing efforts in enhancing the therapeutic options available to individuals suffering from DED.

Current Advances in Mechanisms and Treatment of Dry Eye Disease: Toward Anti-inflammatory and Immunomodulatory Therapy and Traditional Chinese Medicine

Advances in Dry Eye Disease Examination Techniques.

The Alterations of Ocular Surface Metabolism and the Related Immunity Inflammation in Dry Eye

Focusing on systematic therapy of dry eye

New Understanding and Trends in the Diagnosis and Management of Dry Eye

Ocular Surface Ion-Channels Are Closely Related to Dry Eye: Key Research Focus on Innovative Drugs for Dry Eye

Current Advances in Regenerative Strategies for Dry Eye Diseases: A Comprehensive Review

The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options

Advances in the study of examination methods for dry eye

Dry Eye Management: Targeting the Ocular Surface Microenvironment

Recent progress of nanomedicine in managing dry eye disease

Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease

Recent advances in dry eye

Inflammation mechanism and anti-inflammatory therapy of dry eye

Tolerability of Current Treatments for Dry Eye Disease: A Review of Approved and Investigational Therapies

Comprehensive dry eye therapy: overcoming ocular surface barrier and combating inflammation, oxidation, and mitochondrial damage

Newer approaches to dry eye therapy: Nanotechnology, regenerative medicine, and tissue engineering

[Emphasis on Standardization and Refinement in the Diagnosis and Treatment of Dry Eye].

Emphasizing clinical investigation on anti-inflammatory therapy of dry eye

Management of Sjogren's Dry Eye Disease—Advances in Ocular Drug Delivery Offering a New Hope

Dry eye syndrome: comprehensive etiologies and recent clinical trials